Skip to main content
Sign In

Benjamin Bitler, PhD

Assistant Professor, Division of Reproductive Sciences

PhD (2010) in Cancer Biology, University of Arizona Cancer Center


Mail Stop 8613, RC2, Room 3400D

Phone: 303-724-0574

Fax: 303-724-3512

Bitler Lab​

Research interests:

Dr. Bitler received his Ph.D. in Cancer Biology from the University of Arizona Cancer Center. As a graduate student his main interest was in the development of novel anti-breast cancer peptide-based therapies.  He continued his post-doctoral training at Fox Chase Cancer Center and The Wistar Institute in Philadelphia, PA. During this time, he shifted his research focus to ovarian cancer, Wnt signaling, and epigenetics. Dr. Bitler is committed to the fight against cancer through his work to elucidate the impact of cancer-related signaling and epigenetic regulation.

  1. ​Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 Jun 10. doi: 10.1002/mc.23064. [Epub ahead of print] PubMed PMID: 31219654.

    2.    Spotlight on early-career researchers: an interview with Benjamin Bitler. Commun Biol. 2019 Apr 23;2:122. doi: 10.1038/s42003-019-0380-z. eCollection 2019. PubMed PMID: 31044157; PubMed Central PMCID: PMC6478820.

  2. Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK. Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel. Mol Cancer Res. 2019 Mar;17(3):741-750. doi: 10.1158/1541-7786.MCR-18-0451. Epub 2019 Jan 3. PubMed PMID: 30606772.

  3. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018 Nov26;7(11):92. doi: 10.1038/s41389-018-0103-1. PubMed PMID: 30478317; PubMed Central PMCID: PMC6255906.

  4. Baumgartner HK, Rudolph MC, Ramanathan P, Burns V, Webb P, Bitler BG, Stein T, Kobayashi K, Neville MC (2017). Developmental Expression of Claudins in the Mammary Gland. Mammary Gland Biology and NeoplasiaJun;22(2):141-157. doi: 10.1007/s10911-017-9379-6​. PMID: 28455726 

  5. Bitler BG, Watson ZL, Wheeler, LJ, Behbakht K (2017). PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecologic Oncology. doi: 10.1016/j.ygyno.2017.10.003. PMID: 29037806

  6. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramashinghe P, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG*, and Zhang, R (2016). Inhibition of the BET protein BRD4 activity synergizes with cisplatin by targeting ALDH activity through an ALDH1A1 super-enhancer. Cancer ResearchNov 1;76(21):6320-6330. *Co-corresponding author. PMID: 27803105

  7. Wu S, Zhang R and Bitler BG (2016). Arid1a controls tissue regeneration through transcriptional reprogramming. Stem Cell Investigation.  Aug 9;3:35. doi: 10.21037/sci.2016.07.07. PMID: 27582418

  8. Bitler BG, et al (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine. Mar;21(3):231-8. PMID: 25686104

  9. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R (2011). Wnt5a Suppresses Epithelial Ovarian Cancer by Promoting Cellular Senescence. Cancer Research. Oct 1;71(19):6184-94. PMID: 21816908